Form D · Biotechnology
AV Therapeutics, Inc.
White Plains, NY · CIK 0001518635
Offering snapshot reported Apr 20, 2011 · SEC filing
- Reported sold
- Yet to sell Offering amount: $6M
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $5K Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 20, 2011 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $600K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-158694
Convertible debt
Brookville Capital will recieve a 10% sales commission.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Brookville Capital Partners | 102380 | Brookville Capital Partners · CRD 102380 |
Source: Form D, filed Apr 20, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Abraham Mittleman | Director |
| Robert Pollock | Executive |
| Raj Tiwari | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
405 Tarrytown Road Suite 1580
White Plains, NY, 10607
White Plains, NY, 10607